Your browser doesn't support javascript.
loading
Comparative Efficacy and Side Effect Profiles of Interventions for Pediatric Saliva Control: A Cohort Study.
Papandreou, Apostolos; Mahony, Aoife; Breaks, Anne; Absoud, Michael; Fairhurst, Charlie.
Affiliation
  • Papandreou A; Department of Pediatric Neurosciences, Evelina London Children's Hospital, Guys and Saint Thomas' Hospitals, London, UK.
  • Mahony A; Children's Health Ireland Tallaght, and Enable Ireland, Dublin, Ireland.
  • Breaks A; Department of Speech and Language Therapy, Evelina London Children's Hospital, Guys and Saint Thomas' Hospitals, London, UK.
  • Absoud M; Department of Pediatric Neurosciences, Evelina London Children's Hospital, Guys and Saint Thomas' Hospitals, London, UK.
  • Fairhurst C; Department of Pediatric Neurosciences, Evelina London Children's Hospital, Guys and Saint Thomas' Hospitals, London, UK. Electronic address: charlie.fairhurst@gstt.nhs.uk.
J Pediatr ; 265: 113803, 2024 Feb.
Article in En | MEDLINE | ID: mdl-37898423
ABSTRACT

OBJECTIVE:

To compare efficacy and side effect profile data on conservative, behavioral, pharmacological, and surgical treatments used for pediatric saliva control. STUDY

DESIGN:

A cohort study of children (n = 483) referred to a specialty Saliva Control service between May 2014 and November 2019 was performed, using quantitative data from pretreatment and post-treatment questionnaires (the Drooling Impact Scale [DIS], Drooling Rating Scale [DRS]) and recording of side effects. Overall, 483 children were included; treatment choices were based on published international guidelines.

RESULTS:

The greatest improvement was seen after intraglandular botulinum toxin A (BTX-A) injections (n = 207; 551 courses; mean DIS change, 34.7; 95% CI = 29.2-35.7) or duct transpositional surgery (n = 31; mean change in DIS, 29.0; 95% CI, 22.3-35.7). Oral anticholinergics were associated with good outcomes, with no significant statistical difference between glycopyrronium bromide (n = 150; mean DIS change, 21.5; 95% CI, 19.1-24.0) or trihexyphenidyl (n = 87; mean DIS change, 22.4; 95% CI, 18.9-25.8). Inhaled ipratropium bromide was not as efficacious (n = 80; mean DIS change, 11.1; 95% CI, 8.9-13.3). Oromotor programs were used in a selected group with reliable outcomes (n = 9; mean DIS change, 13.0). Side effects were consistent with previous studies. Overall, in cases of milder severity, enterally administered therapies provided a good first-line option. With more severe problems, BTX-A injections or saliva duct transpositional surgery were more effective and well tolerated.

CONCLUSIONS:

We describe a large, single-center pediatric saliva control cohort, providing direct comparison of the efficacy and side effect profiles for all available interventions and inform clinical practice for specialists when considering different options. BTX-A injections or saliva duct transpositional surgery seem to be more effective for saliva control that is more severe.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sialorrhea / Cerebral Palsy / Botulinum Toxins, Type A Limits: Child / Humans Language: En Journal: J Pediatr Year: 2024 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sialorrhea / Cerebral Palsy / Botulinum Toxins, Type A Limits: Child / Humans Language: En Journal: J Pediatr Year: 2024 Document type: Article Affiliation country:
...